Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 1, 2006, Pages 1-5

  DeJesus, Edwin ^a   Berger, Daniel ^b   Markowitz, Martin ^c   Cohen, Calvin ^d   Hawkins, Trevor ^e   Ruane, Peter ^f   Elion, Richard ^g   Farthing, Charles ^h   Zhong, Lijie ⁱ   Cheng, Andrew K ⁱ   McColl, Damian ⁱ   Kearney, Brian P ^i,j  

^a ORLANDO IMMUNOLOGY CENTER   (United States)

^b Northstar Medical Center   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d Boston Community Research Initiative of New England   (United States)

^e Southwest Comprehensive AIDS Care Research and Education   (United States)

^f Light Source Medical   (United States)

^g Infectious Diseases Clinical Research Program   (United States)

^h AIDS HEALTHCARE FOUNDATION   (United States)

ⁱ GILEAD SCIENCES   (United States)

^j NONE   (United States)

more..

Author keywords

GS 9137; HIV; Integrase; JTK 303; Pharmacokinetics pharmacodynamics

Indexed keywords

6 (3 CHLORO 2 FLUOROBENZYL) 1 (1 HYDROXY 3 METHYLBUTAN 2 YL) 7 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; ALANINE AMINOTRANSFERASE; AMYLASE; ANTIVIRUS AGENT; CREATINE KINASE; GS 9137; INTEGRASE INHIBITOR; PLACEBO; RITONAVIR; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONOTHERAPY; MUSCLE SPASM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SIDE EFFECT; STEADY STATE; THERAPY EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; HIV INFECTIONS; HIV INTEGRASE; HUMANS; QUINOLONES;

EID: 33748113778     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000233308.82860.2f     Document Type: Article

References (24)

1. Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. AIDSInfo Web site. Available at: http://AIDSinfo.nih.gov. Accessed October 6, 2005.
2. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287(5453):646-650.
3. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science. 2004;305(5683):528-532.
4. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005;4(3):236-248.
5. Sinha S, Grandgenett DP. Recombinant human immunodeficiency virus type 1 integrase exhibits a capacity for full-site integration in vitro that is comparable to that of purified preintegration complexes from virus-infected cells. J Virol. 2005;79(13):8208-8216.
6. Matsuzaki Y, Watanabe W, Yamataka K, et al. JTK-303/GS-9137, a novel small molecule inhibitor of HIV-1 integrase: anti-HIV activity profile and pharmacokinetics in animals. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Poster number 508.
7. Mathias A, Jain A, Hui J, et al. Pharmacokinetic characterization of GS-9137, an HIV integrase inhibitor dosed with ritonavir. Paper presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 20-22, 2006; Lisbon, Portugal.
8. Kawaguchi I, Ishikawa T, Ishibashi M, et al. Safety and pharmacokinetics of single oral dose of JTK-303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Poster number 580.
9. Wilson JW, Bean P, Robins T, et al. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR Method, the HIV PRT GeneChip Assay, and the HIV-1 RT Line Probe Assay. J Clin Microbiol. 2000;38(8):3022-3028.
10. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev. 2002;15(2):247-277.
11. Erali M, Page S, Reimer LG, et al. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J Clin Microbiol. 2001;39(6):2157-2165.
12. Morales-Ramirez JO, Teppler H, Kovacs C, et al. Antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in ART-naive HIV-1 infected patients. Paper presented at: 10th European AIDS Conference (EACS); November 17-20, 2005; Dublin, Ireland. Abstract LBPS1/6.
13. Lalezari J, Thompson M, Kumar P, et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS. 2005;19(14):1443-1448.
14. Arasteh K, Clumeck N, Pozniak A, et al. TMC114/ritonavir substitution for protease inhibitor(s) in a nonsuppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS. 2005;19(9):943-947.
15. McCallister S, Valdez H, Curry K, et al. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35(4):376-382.
16. Kearney BP, Mathias M, Zhong L, et al. Pharmacokinetics/pharmacodynamics of GS-9137 an HIV integrase inhibitor. Paper presented at: 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 20-22, 2006; Lisbon, Portugal.
17. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med. 2005;13(1):51-57.
18. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373(6510):123-126.
19. Stein DS, Fish DG, Bilello JA, et al. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS. 1996;10(5):485-492.
20. Gieschke R, Fotteler B, Buss N, et al. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet. 1999;37(1):75-86.
21. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15(1):F1-F9.
22. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32(1):18-29.
23. Grinsztejn B, Nguyen B, Katlama C, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Presentation no. 159LB.
24. Little S, Drusano G, Schooley R, et al. Antiretroviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1 infected patients. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, MA. Abstract 161.